Chemistry:Plasma-lyte
From HandWiki
Plasma-Lyte is a crystalloid solution for intravenous infusion, with varying electrolyte formulation depending on market. Generally the solution has a composition that mimics human physiological plasma electrolyte concentrations, osmolality and pH.[1]
It is manufactured and marketed by Baxter International Inc.[2] and available as a generic medication.[3][4]
Plasma-lyte 148 (pH7.4)
Plasma-Lyte 148 is a market-specific solution available in the United Kingdom and Australia, among others and has the following composition:[5]
- Sodium 140 mmol/L
- Potassium 5 mmol/L
- Magnesium 1.5 mmol/L
- Chloride 98 mmol/L
- Acetate 27 mmol/L
- Gluconate 23 mmol/L
A Plasma-Lyte 148 with 5% glucose is also manufactured by Baxter[6].
References
- ↑ 1: Rizoli S. PlasmaLyte. J Trauma. 2011 May;70(5 Suppl):S17-8. doi: 10.1097/TA.0b013e31821a4d89. PMID 21841561.
- ↑ 2: Baxter. Plasma-Lyte 148 product information. 2013. available at URL: http://www.baxterhealthcare.com.au/downloads/healthcare_professionals/cmi_pi/plasmalyte148_pi.pdf
- ↑ "2022 First Generic Drug Approvals". 3 March 2023. https://www.fda.gov/drugs/drug-and-biologic-approval-and-ind-activity-reports/2022-first-generic-drug-approvals.
- ↑ "Competitive Generic Therapy Approvals". 29 June 2023. https://www.fda.gov/drugs/generic-drugs/competitive-generic-therapy-approvals.
- ↑ "TGA eBS - Product and Consumer Medicine Information Licence". https://www.ebs.tga.gov.au/ebs/picmi/picmirepository.nsf/pdf?OpenAgent&id=CP-2015-PI-01487-1.
- ↑ "TGA eBS - Product and Consumer Medicine Information Licence". https://www.ebs.tga.gov.au/ebs/picmi/picmirepository.nsf/pdf?OpenAgent&id=CP-2010-PI-04253-3&d=20260810172310101.
 |  |
